asabaliauskas on DSK5VPTVN1PROD with NOTICES

Federal Register / Vol. 80, No. 92 / Wednesday, May 13, 2015 / Notices 

SUPPLEMENTARY INFORMATION: 

Authority: 42 CFR 83.9–83.12. 

Pursuant to 42 CFR 83.12, the initial 

proposed definition for the class being 

evaluated, subject to revision as 

warranted by the evaluation, is as 

follows: 

Facility: Blockson Chemical 

Company. 

Location: Joliet, Illinois. 

Job Titles and/or Job Duties: All 

workers who worked in any area. 

Period of Employment: July 1, 1960 

through December 31, 1991. 

John Howard, 

Director, National Institute for Occupational 

Safety and Health. 

[FR Doc. 2015–11471 Filed 5–12–15; 8:45 am] 

BILLING CODE 4163–19–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Meeting of the National Vaccine 

Advisory Committee 

AGENCY: National Vaccine Program 

Office, Office of the Assistant Secretary 

for Health, Office of the Secretary, 

Department of Health and Human 

Services. 

ACTION: Notice. 

SUMMARY: As stipulated by the Federal 

Advisory Committee Act, the 

Department of Health and Human 

Services (HHS) is hereby giving notice 

that the National Vaccine Advisory 

Committee (NVAC) will hold a meeting 

on June 9–10, 2015. The meeting is open 

to the public. However, pre-registration 

is required for both public attendance 

and public comment. Individuals who 

wish to attend the meeting and/or 

participate in the public comment 

session should register at http:// 

www.hhs.gov/nvpo/nvac. Participants 

may also register by emailing nvpo@ 

hhs.gov or by calling 202–690–5566 and 

providing their name, organization, and 

email address. 

DATES: The meeting will be held on June 

9–10, 2015. The meeting times and 

agenda will be posted on the NVAC 

Web site at http://www.hhs.gov/nvpo/ 

nvac as soon as they become available. 

ADDRESSES: U.S. Department of Health 

and Human Services, Hubert H. 

Humphrey Building, Room 800, 200 

Independence Avenue SW., 

Washington, DC 20201. 

The meeting can also be accessed 

through a live webcast the day of the 

meeting. For more information, visit 

http://www.hhs.gov/nvpo/nvac/ 

meetings/upcomingmeetings/ 

index.html. 

FOR FURTHER INFORMATION CONTACT: 

National Vaccine Program Office, U.S. 

Department of Health and Human 

Services, Room 715–H, Hubert H. 

Humphrey Building, 200 Independence 

Avenue SW., Washington, DC 20201. 

Phone: (202) 690–5566; email: nvpo@ 

hhs.gov. 

SUPPLEMENTARY INFORMATION: Pursuant 

to Section 2101 of the Public Health 

Service Act (42 U.S.C. 300aa–1), the 

Secretary of Health and Human Services 

was mandated to establish the National 

Vaccine Program to achieve optimal 

prevention of human infectious diseases 

through immunization and to achieve 

optimal prevention against adverse 

reactions to vaccines. The NVAC was 

established to provide advice and make 

recommendations to the Director of the 

National Vaccine Program on matters 

related to the Program’s responsibilities. 

The Assistant Secretary for Health 

serves as Director of the National 

Vaccine Program. 

The June NVAC meeting will include 

the presentation of recommendations 

from several of the NVAC working 

groups for deliberation and vote. The 

Vaccine Confidence Working Group will 

present their report and 

recommendations for measuring and 

evaluating how confidence in vaccines 

impacts the optimal use of 

recommended childhood vaccines in 

the United States. Following an update 

on current efforts by national 

stakeholders to improve Human 

Papilloma Virus (HPV) vaccine uptake 

among adolescents, the HPV working 

group will also present their report and 

recommendations identifying existing 

best practices to increase the use of the 

HPV vaccine in young adolescents. 

NVAC will review analyses and 

proposed recommendations on how 

vaccines could play more prominently 

in efforts described in the President’s 

National Strategy and Action Plan to 

Combat Antibiotic Resistant Bacteria. 

An overview of the Vaccine Safety 

Research Agenda that was released on 

the NVPO Web site in February 2015 

will also be provided. The Vaccine 

Safety Research Agenda outlines the 

efforts of federal agencies on vaccine 

safety and the ongoing and planned 

associated scientific activities and 

interagency coordination that contribute 

to the safety system. Informational 

presentations will also be provided to 

inform NVAC members of recent 

developments impacting the vaccine 

landscape including Congressional 

efforts to support the research and 

development of new vaccine products 

through the 21st Century Cures 

Initiative. More information on the 

meeting agenda will be posted prior to 

the meeting on the NVAC Web site: 

http://www.hhs.gov/nvpo/nvac. 

Public attendance at the meeting is 

limited to the available space. 

Individuals who plan to attend and 

need special assistance, such as sign 

language interpretation or other 

reasonable accommodations, should 

notify the National Vaccine Program 

Office at the address/phone listed above 

at least one week prior to the meeting. 

For those unable to attend in person, a 

live webcast will be available. More 

information on registration and 

accessing the webcast can be found at 

http://www.hhs.gov/nvpo/nvac/ 

meetings/upcomingmeetings/ 

index.html. 

Members of the public will have the 

opportunity to provide comments at the 

NVAC meeting during the public 

comment periods designated on the 

agenda. Public comments made during 

the meeting will be limited to three 

minutes per person to ensure time is 

allotted for all those wishing to speak. 

Individuals are also welcome to submit 

their written comments. Written 

comments should not exceed three 

pages in length. Individuals submitting 

written comments should email their 

comments to the National Vaccine 

Program Office (nvpo@hhs.gov) at least 

five business days prior to the meeting. 

Dated: May 4, 2015. 

Bruce Gellin, 

Executive Secretary, National Vaccine 

Advisory Committee, Deputy Assistant 

Secretary for Health, Director, National 

Vaccine Program Office. 

[FR Doc. 2015–11476 Filed 5–12–15; 8:45 am] 

BILLING CODE 4150–44–P 

27329 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Determination Concerning a Petition 

To Add a Class of Employees To the 

Special Exposure Cohort 

AGENCY: National Institute for 

Occupational Safety and Health 

(NIOSH), Centers for Disease Control 

and Prevention, Department of Health 

and Human Services (HHS). 

ACTION: Notice. 

SUMMARY: HHS gives notice of a 

determination concerning a petition to 

add a class of employees from the St. 

Louis Airport Storage Site (SLAPS) in 

St. Louis, Missouri, to the Special 

Exposure Cohort (SEC) under the Energy 

Employees Occupational Illness 

Compensation Program Act of 2000 

(EEOICPA). 
Ve 00000 Frm 00047 Fmt 4703 Sfmt 4703 E:\FR\FM\13MYN1.SGM 13MYN1

asabaliauskas on DSK5VPTVN1PROD with NOTICES

rDate Sep<11>2014 17:27 May 12, 2015 Jkt 235001 PO

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Diabetes and 

Digestive and Kidney Diseases; Notice 

of Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Diabetes and Digestive and Kidney Diseases 

Special Emphasis Panel; NIDDK DEM 

Fellowship Grant Review. 

Date: May 31–June 2, 2015. 

Time: 6:00 p.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Melrose Georgetown Hotel, 2430 

Pennsylvania Avenue NW., Washington, DC 

20037. 

27330 

FOR FURTHER INFORMATION CONTACT: 

Stuart L. Hinnefeld, Director, Division 

of Compensation Analysis and Support, 

National Institute for Occupational 

Safety and Health (NIOSH), 1090 

Tusculum Avenue, MS C–47, 

Cincinnati, OH 45226–1938, Telephone 

1–877–222–7570. Information requests 

can also be submitted by email to 

DCAS@CDC.GOV. 

SUPPLEMENTARY INFORMATION: 

Authority: [42U.S.C.7384q]. 

On April 9, 2015, the Secretary of 

HHS determined that the following class 

of employees does not meet the 

statutory criteria for addition to the SEC 

as authorized under EEOICPA: 

All employees of the U.S. Department of 

Energy (DOE), its predecessor agencies, and 

their contractors and subcontractors who 

worked at the St. Louis Airport Storage Site 

in St. Louis, Missouri, from November 3, 

1971, through December 31, 1973, and from 

January 1, 1984,through December 31, 1998. 

John Howard, 

Director, National Institute for Occupational 

Safety and Health. 

[FR Doc. 2015–11475 Filed 5–12–15; 8:45 am] 

BILLING CODE 4163–19–P 

Federal Register / Vol. 80, No. 92 / Wednesday, May 13, 2015 / Notices 

Contact Person: Carol J. Goter-Robinson, 

Ph.D., Scientific Review Officer, Review 

Branch, DEA, NIDDK, National Institutes of 

Health, Room 748, 6707 Democracy 

Boulevard, Bethesda, MD 20892–5452, (301) 

594–7791, goterrobinsonc@ 

extra.niddk.nih.gov. 

Name of Committee: National Institute of 

Diabetes and Digestive and Kidney Diseases 

Special Emphasis Panel; Member Conflict 

SEP. 

Date: June 5, 2015. 

Time: 7:30 a.m. to 2:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Embassy Suites Chevy Chase 

Pavilion, 4300 Military Road NW., 

Washington, DC 20015. 

Contact Person: Xiaodu Guo, MD, Ph.D., 

Scientific Review Officer, Review Branch, 

DEA, NIDDK, National Institutes of Health, 

Room 761, 6707 Democracy Boulevard, 

Bethesda, MD 20892–5452, (301) 594–4719, 

guox@extra.niddk.nih.gov. 

Name of Committee: National Institute of 

Diabetes and Digestive and Kidney Diseases 

Special Emphasis Panel; PAR–12–265: 

NIDDK Ancillary Studies (R01). 

Date: June 11, 2015. 

Time: 11:00 a.m. to 1:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, Two 

Democracy Plaza, 6707 Democracy 

Boulevard, Bethesda, MD 20892, (Telephone 

Conference Call). 

Contact Person: Jian Yang, Ph.D., Scientific 

Review Officer, Review Branch, DEA, 

NIDDK, National Institutes of Health, Room 

755, 6707 Democracy Boulevard, Bethesda, 

MD 20892–5452, (301) 594–7799, yangj@ 

extra.niddk.nih.gov. 

Name of Committee: National Institute of 

Diabetes and Digestive and Kidney Diseases 

Special Emphasis Panel; GPCR Signaling in 

Bone Program Project (PO1). 

Date: June 16, 2015. 

Time: 11:00 a.m. to 2:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, Two 

Democracy Plaza, 6707 Democracy 

Boulevard, Bethesda, MD 20892, (Telephone 

Conference Call). 

Contact Person: Dianne Camp, Ph.D., 

Scientific Review Officer, Review Branch, 

DEA, NIDDK, National Institutes of Health, 

Room 756, 6707 Democracy Boulevard, 

Bethesda, MD 20892–2542, 301–594–7682, 

campd@extra.niddk.nih.gov. 

Name of Committee: National Institute of 

Diabetes and Digestive and Kidney Diseases 

Special Emphasis Panel; Limited 

Competition for the Continuation of the 

Diabetes Prevention Program Outcomes 

Study (Collaborative U01). 

Date: June 22, 2015. 

Time: 11:00 a.m. to 4:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, Two 

Democracy Plaza, 6707 Democracy 

Boulevard, Bethesda, MD 20892, (Telephone 

Conference Call). 

Contact Person: Dianne Camp, Ph.D., 

Scientific Review Officer, Review Branch, 

DEA, NIDDK, National Institutes of Health, 

Room 756, 6707 Democracy Boulevard, 

Bethesda, MD 20892–2542, 301–594–7682, 

campd@extra.niddk.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.847, Diabetes, 

Endocrinology and Metabolic Research; 

93.848, Digestive Diseases and Nutrition 

Research; 93.849, Kidney Diseases, Urology 

and Hematology Research, National Institutes 

of Health, HHS) 

Dated: May 8, 2015. 

David Clary, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2015–11560 Filed 5–12–15; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Office of the Director, National 

Institutes of Health; Notice of Meeting 

Pursuant to section 10(a) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of a meeting of the 

Recombinant DNA Advisory Committee. 

The meeting will be open to the 

public, with attendance limited to space 

available. Individuals who plan to 

attend and need special assistance, such 

as sign language interpretation or other 

reasonable accommodations, should 

notify the Contact Person listed below 

in advance of the meeting. 

Name of Committee: Recombinant DNA 

Advisory Committee. 

Date: June 9–10, 2015. 

Time: June 9, 2015, 12:00 p.m. to 5:10 p.m. 

Agenda: The NIH Recombinant DNA 

Advisory Committee (RAC) will review and 

discuss selected human gene transfer 

protocols and related data management 

activities. For more information, please check 

the meeting agenda at OBA Meetings Page 

(available at the following URL: http:// 

osp.od.nih.gov/office-biotechnologyactivities/event/2015-06-09-160000-2015-06-

10-210000/rac-meeting). 

Place: National Institutes of Health, 

Natcher Building, Conference Room E1/E2, 

45 Center Drive, Bethesda, MD 20892. 

Time: June 10, 2015, 8:30 a.m. to 5:00 p.m. 

Agenda: The NIH Recombinant DNA 

Advisory Committee (RAC) will be holding a 

workshop to discuss Cytokine Release 

Syndrome after T Cell Immunotherapy. The 

focus of this workshop will be to review CRS 

experiences and establish a uniform 

definition, develop grading criteria, and 

optimize management strategies for CRS. For 

more information, please check the meeting 

agenda at OBA Meetings Page (available at 

the following URL: http://osp.od.nih.gov/ 

office-biotechnology-activities/event/2015-

06-09-160000-2015-06-10-210000/racmeeting).